Stručni rad
Intravitreal Bevacizumab (Avastin) in Treatment of Neovascular Age-related Macular Degeneration
Ratimir Lazić
Nikica Gabrić
Iva Dekaris
Borna Šarić
Morena Gavrić
Sažetak
To evaluate the efficacy and safety of intravitreal bevacizumab in treatment of minimally classic and occult choroidal
neovascularization secondary to age-related macular disease 48 eyes of 48 patients (mean age of 74.8) included in this
prospective, noncomparative, interventional case series. Median follow-up was 18 weeks (6–24). Intravitreal bevacizumab
injection of 0.05 mL (1.25 mg) was administered at baseline and in 6 week intervals until leakage resolved, and repeated
in case of leakage recurrence. Visual acuity (VA) improved in the majority of patients (mean baseline VA=1.078
log MAR) by mean increase of 1.32 lines (last follow-up) (p=0.001). Central foveal thickness and total macular volume
decreased by 51 μm (p=0.01) and 0.84 mm3 (p<0.0001) respectively. No serious complications were observed. As initial
therapy, intravitreal bevacizumab appears to be safe and effective. A significant functional and anatomical improvement
was noted in majority of patients and maintained during follow-up.
Ključne riječi
bevacizumab; ranibizumab; pegaptanib
Hrčak ID:
27429
URI
Datum izdavanja:
16.1.2007.
Posjeta: 926 *